Sacituzumab govitecan-hziy and Neutropenia

In this article, we will discuss Sacituzumab govitecan-hziy and Neutropenia. So, let’s get started.

Sacituzumab govitecan-hziy and Neutropenia

Sacituzumab govitecan-hziy can cause severe or life-threatening neutropenia. Withhold Sacituzumab govitecan-hziy for absolute neutrophil count below 1500/mm3 on Day 1 of any cycle or neutrophil count below 1000/mm3 on Day 8 of any cycle. Withhold Sacituzumab govitecan-hziy for neutropenic fever. Dose modifications may be required due to neutropenia.

Febrile neutropenia occurred in 6% (24/408) patients treated with Sacituzumab govitecan-hziy, including 8% (9/108) patients with mTNBC after at least two prior therapies. Less than 1% (1/408) of patients had febrile neutropenia leading to permanent discontinuation.

The incidence of Grade 1-4 neutropenia was 64% in patients with mTNBC (n=108). In all patients treated with Sacituzumab govitecan-hziy (n=408), the incidence of Grade1-4 neutropenia was 54%; Grade 4 neutropenia occurred in 13%. Less than
1% (2/408) of patients permanently discontinued treatment due to neutropenia.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.